Organon stock sits 0.51 percent below its 52-week high

Published on 10/15/2026 at 22:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Organon's P/E is 17.87 on October 15, 2026. Organon stock costs EUR 12.25 on October 15, 2026 at 10:45 p.m. CEST.

Trading range and valuation

Organon stock stood 0.51 percent below its 52-week high on October 15, 2026.
Organon's P/E was 17.87 on October 15, 2026.
Organon stock costs EUR 12.25 at Lang & Schwarz on October 15, 2026 at 10:45 p.m. CEST.
Organon's market capitalization was USD 3.6 billion on October 15, 2026.

OGN, US68622V1061, Illustration mit AI erstellt.

Organon stock stood 0.51 percent below its 52-week high on October 15, 2026, placing the share near the upper end of its USD 5.69 to USD 13.83 annual range. At Lang & Schwarz, the stock was trading at EUR 12.25 on October 15, 2026 at 10:45 p.m. CEST.

The range leaves little room

Organon's NYSE quote was USD 13.76 at 4:00 p.m. ET on October 15, 2026. That level was USD 0.07 below the 52-week high and USD 8.07 above the 52-week low, showing how sharply the stock has moved within its annual band. The same quote carried a daily gain of 0.15 percent and volume of 1,979,871 shares, against an average volume of 2,657,251 shares.

The company identifies itself as NYSE: OGN on its Organon investor-relations page. Organon focuses on prescription medicines, women's health products, biosimilars and established brands. Its portfolio includes contraceptive products, fertility treatments and therapies in areas such as cardiovascular care, respiratory medicine and dermatology.

Valuation and income profile

Organon's market capitalization was USD 3.6 billion on October 15, 2026. Its P/E was 17.87, while the trailing dividend yield was 0.01 percent. The company reported USD 1.56 billion in revenue and USD 108.0 million in net income for the second quarter of 2026, with diluted earnings per share of USD 0.40. These figures place revenue below the USD 1.60 billion reported for the first quarter of 2026, while net income also fell from USD 146.0 million.

Comparison with peers

OGN: plus 0.15 percent, P/E 17.87, market capitalization USD 3.6 billion
Viatris (Nasdaq, USD): plus 4.47 percent, P/E minus 50.61, market capitalization USD 20.9 billion
Teva Pharmaceutical Industries (NYSE, USD): plus 0.96 percent, P/E 69.55, market capitalization USD 47.9 billion

Trading position

Organon's combination of a near-high share price, a 17.87 P/E and a 0.01 percent dividend yield gives the stock a clearly defined valuation profile. The company's second-quarter revenue of USD 1.56 billion remains the most recent reported operating figure, while the annual price range provides the main market reference for the current quote.

The further course of trading is shown by the continuously updated real-time quote of Organon stock.